Vertex Pharmaceuticals announced it has agreed to acquire Crinetics Pharmaceuticals.
9 reports, 6 independent
Updated Sep 14
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 9
- Developments
- 2
- Repetition
- 78%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vertex Pharmaceuticals announced it has agreed to acquire Crinetics Pharmaceuticals.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.The acquisition grants Vertex access to Crinetics' pipeline assets, focusing on endocrine diseases.1 source
Vertex targets Crinetics in acquisition news.1 source
Keep exploring
The entities involved
-
Vertex Pharmaceuticals
American pharmaceutical company
-
Crinetics Pharmaceuticals
company in San Diego, United States
Nothing else this week.
Related events
- Direct financial comparison of two market rivals: Vertex Pharmaceuticals and Prothena Corporation plc.
- Goldman Sachs updated its top stock picks, removing Interactive Brokers and adding Vertex Pharmaceuticals.
- Vertex Pharmaceuticals trades on Nasdaq, files reports with the SEC, and has an executive named Duncan McKechnie.
- Vertex Pharmaceuticals had required 13F filings with the SEC and its stock traded on the Nasdaq exchange on September 8, 2026.
- Vertex Pharmaceuticals presented updates at a Wells Fargo conference on September 12, 2026.